-
1
-
-
10744221008
-
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
-
Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science.2004;303(5661):1201-4.
-
(2004)
Science
, vol.303
, Issue.5661
, pp. 1201-1204
-
-
Altmann, S.W.1
Davis Jr., H.R.2
Zhu, L.J.3
Yao, X.4
Hoos, L.M.5
Tetzloff, G.6
-
2
-
-
77949485460
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial
-
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet.2010;375(9719):998-1006.
-
(2010)
Lancet.
, vol.375
, Issue.9719
, pp. 998-1006
-
-
Raal, F.J.1
Santos, R.D.2
Blom, D.J.3
Marais, A.D.4
Charng, M.J.5
Cromwell, W.C.6
-
3
-
-
33846151732
-
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
-
Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med.2007;356(2):148-56.
-
(2007)
N Engl J Med
, vol.356
, Issue.2
, pp. 148-156
-
-
Cuchel, M.1
Bloedon, L.T.2
Szapary, P.O.3
Kolansky, D.M.4
Wolfe, M.L.5
Sarkis, A.6
-
4
-
-
34047183679
-
CETP inhibitors to increase HDL cholesterol levels
-
Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med.2007;356(13):1364-6.
-
(2007)
N Engl J Med
, vol.356
, Issue.13
, pp. 1364-1366
-
-
Tall, A.R.1
-
5
-
-
66349126280
-
PCSK9: A convertase that coordinates LDL catabolism
-
Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res.2009;50 Suppl:S172-7.
-
(2009)
J Lipid Res.
, vol.50
, Issue.SUPPL.
-
-
Horton, J.D.1
Cohen, J.C.2
Hobbs, H.H.3
-
6
-
-
67649834099
-
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
-
Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009;106(24):9546-7.
-
(2009)
Proc Natl Acad Sci U S A.
, vol.106
, Issue.24
, pp. 9546-9547
-
-
Steinberg, D.1
Witztum, J.L.2
-
7
-
-
0033552883
-
Atherosclerosis--an inflammatory disease
-
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
-
(1999)
N Engl J Med.
, vol.340
, Issue.2
, pp. 115-126
-
-
Ross, R.1
-
8
-
-
17644412023
-
Inflammation, atherosclerosis, and coronary artery disease
-
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95.
-
(2005)
N Engl J Med.
, vol.352
, Issue.16
, pp. 1685-1695
-
-
Hansson, G.K.1
-
9
-
-
21544467275
-
Pathophysiology of coronary artery disease
-
Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8.
-
(2005)
Circulation.
, vol.111
, Issue.25
, pp. 3481-3488
-
-
Libby, P.1
Theroux, P.2
-
10
-
-
0042117898
-
-
Recomendations for Improving Cholesterol Measurement. National Heart, Lung and Blood Institute; NIH Publication n° 93-2964. Bethesda, MD
-
Recomendations for Improving Cholesterol Measurement. A report from the Laboratory Standardization Panel of the National Cholesterol Education Program. National Heart, Lung and Blood Institute; NIH Publication n° 93-2964. Bethesda, MD; 1993.
-
(1993)
A report from the Laboratory Standardization Panel of the National Cholesterol Education Program.
-
-
-
11
-
-
56449117739
-
IV Diretriz brasileira sobre dislipidemias e prevenção da aterosclerose
-
Sociedade Brasileira de Cardiologia
-
Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, et al.; Sociedade Brasileira de Cardiologia. IV Diretriz brasileira sobre dislipidemias e prevenção da aterosclerose. Arq Bras Cardiol. 2007;88(supl 1):1-18.
-
(2007)
Arq Bras Cardiol.
, vol.88
, Issue.SUPPL. 1
, pp. 1-18
-
-
Sposito, A.C.1
Caramelli, B.2
Fonseca, F.A.3
Bertolami, M.C.4
Afiune Neto, A.5
Souza, A.D.6
-
12
-
-
0032510639
-
Prediction of coronary heart disease using risk factor categories
-
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
-
(1998)
Circulation.
, vol.97
, Issue.18
, pp. 1837-1847
-
-
Wilson, P.W.1
D'Agostino, R.B.2
Levy, D.3
Belanger, A.M.4
Silbershatz, H.5
Kannel, W.B.6
-
13
-
-
0035897696
-
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
-
(2001)
JAMA.
, vol.285
, Issue.19
, pp. 2486-2497
-
-
-
14
-
-
33846996345
-
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score
-
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611-9.
-
(2007)
JAMA.
, vol.297
, Issue.6
, pp. 611-619
-
-
Ridker, P.M.1
Buring, J.E.2
Rifai, N.3
Cook, N.R.4
-
15
-
-
57749210419
-
C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men
-
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-51.
-
(2008)
Circulation.
, vol.118
, Issue.22
, pp. 2243-2251
-
-
Ridker, P.M.1
Paynter, N.P.2
Rifai, N.3
Gaziano, J.M.4
Cook, N.R.5
-
16
-
-
39549093148
-
General cardiovascular risk profile for use in primary care: The Framingham Heart Study
-
D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
-
(2008)
Circulation.
, vol.117
, Issue.6
, pp. 743-753
-
-
D'Agostino, R.B.1
Vasan, R.S.2
Pencina, M.J.3
Wolf, P.A.4
Cobain, M.5
Massaro, J.M.6
-
17
-
-
33644868473
-
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
-
Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791-8.
-
(2006)
Circulation.
, vol.113
, Issue.6
, pp. 791-798
-
-
Lloyd-Jones, D.M.1
Leip, E.P.2
Larson, M.G.3
D'Agostino, R.B.4
Beiser, A.5
Wilson, P.W.6
-
18
-
-
84856245226
-
Lifetime risks of cardiovascular disease
-
Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321-9.
-
(2012)
N Engl J Med.
, vol.366
, Issue.4
, pp. 321-329
-
-
Berry, J.D.1
Dyer, A.2
Cai, X.3
Garside, D.B.4
Ning, H.5
Thomas, A.6
-
19
-
-
49649083150
-
Lifetime risk of cardiovascular diseaseamong individuals with and without diabetes stratified by obesity status in the Framingham Heart Study
-
Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular diseaseamong individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008;31(8):1582-4.
-
(2008)
Diabetes Care.
, vol.31
, Issue.8
, pp. 1582-1584
-
-
Fox, C.S.1
Pencina, M.J.2
Wilson, P.W.3
Paynter, N.P.4
Vasan, R.S.5
D'Agostino Sr., R.B.6
-
20
-
-
79960205374
-
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
European Society of Cardiology (ESC); European Atherosclerosis Society (EAS)
-
Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.
-
(2011)
Atherosclerosis.
, vol.217
, Issue.1
, pp. 3-46
-
-
Catapano, A.L.1
Reiner, Z.2
De Backer, G.3
Graham, I.4
Taskinen, M.R.5
Wiklund, O.6
-
21
-
-
84865312335
-
Common carotid intima-media thicknessmeasurements in cardiovascular risk prediction: A meta-analysis
-
Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common carotid intima-media thicknessmeasurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308(8):796-803.
-
(2012)
JAMA.
, vol.308
, Issue.8
, pp. 796-803
-
-
Den Ruijter, H.M.1
Peters, S.A.2
Anderson, T.J.3
Britton, A.R.4
Dekker, J.M.5
Eijkemans, M.J.6
-
22
-
-
84865320778
-
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals
-
Yeboah J, McClelland LR, Polonski TS, Burke GL, Sibley CT, O'Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788-95.
-
(2012)
JAMA.
, vol.308
, Issue.8
, pp. 788-795
-
-
Yeboah, J.1
McClelland, L.R.2
Polonski, T.S.3
Burke, G.L.4
Sibley, C.T.5
O'Leary, D.6
-
23
-
-
79953065575
-
Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A guideline from the American Heart Association
-
Erratum in: Circulation. 2011;123(22):e624. Circulation. 2011;124(16):e427
-
Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62. Erratum in: Circulation. 2011;123(22):e624. Circulation. 2011;124(16):e427.
-
(2011)
Circulation
, vol.123
, Issue.11
, pp. 1243-1262
-
-
Mosca, L.1
Benjamin, E.J.2
Berra, K.3
Bezanson, J.L.4
Dolor, R.J.5
Lloyd-Jones, D.M.6
-
24
-
-
25144459980
-
The metabolic syndrome--a new worldwide definition
-
IDF Epidemiology Task Force Consensus Group
-
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366(9491):1059-62.
-
(2005)
Lancet.
, vol.366
, Issue.9491
, pp. 1059-1062
-
-
Alberti, K.G.1
Zimmet, P.2
Shaw, J.3
-
25
-
-
33744828023
-
Global Guideline for Type 2 Diabetes: Recommendations for standard, comprehensive, and minimal care
-
IDF Clinical Guidelines Task Force
-
IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579-93.
-
(2006)
Diabet Med.
, vol.23
, Issue.6
, pp. 579-593
-
-
-
26
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
-
JUPITER Trial Study Group
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-82.
-
(2009)
Lancet.
, vol.373
, Issue.9670
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
-
27
-
-
4444382796
-
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
-
INTERHEART Study Investigators
-
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
-
(2004)
Lancet.
, vol.364
, Issue.9438
, pp. 937-952
-
-
Yusuf, S.1
Hawken, S.2
Ounpuu, S.3
Dans, T.4
Avezum, A.5
Lanas, F.6
-
28
-
-
36549034768
-
Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
-
Prospective Studies Collaboration
-
Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39.
-
(2007)
Lancet.
, vol.370
, Issue.9602
, pp. 1829-1839
-
-
Lewington, S.1
Whitlock, G.2
Clarke, R.3
Sherliker, P.4
Emberson, J.5
Halsey, J.6
-
29
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
-
Cholesterol Treatment Trialists' (CTT) Collaboration
-
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
-
(2010)
Lancet.
, vol.376
, Issue.9753
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
Holland, L.E.4
Reith, C.5
Bhala, N.6
-
30
-
-
84871260146
-
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis
-
Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-9.
-
(2012)
J Am Coll Cardiol.
, vol.60
, Issue.25
, pp. 2631-2639
-
-
Ference, B.A.1
Yoo, W.2
Alesh, I.3
Mahajan, N.4
Mirowska, K.K.5
Mewada, A.6
-
31
-
-
78649884740
-
Statins and stroke: Potential mechanisms for neurovascular protection
-
Fonseca FA, França CN, Póvoa RM, Izar MC. [Statins and stroke: potential mechanisms for neurovascular protection]. Rev Neurol. 2010;51(9):551-60.
-
(2010)
Rev Neurol.
, vol.51
, Issue.9
, pp. 551-560
-
-
Fonseca, F.A.1
França, C.N.2
Póvoa, R.M.3
Izar, M.C.4
-
32
-
-
84868201763
-
Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials
-
Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;110(10):1468-76.
-
(2012)
Am J Cardiol.
, vol.110
, Issue.10
, pp. 1468-1476
-
-
Robinson, J.G.1
Wang, S.2
Jacobson, T.A.3
-
33
-
-
35848958806
-
Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese
-
Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res. 2007;48(11):2499-505.
-
(2007)
J Lipid Res.
, vol.48
, Issue.11
, pp. 2499-2505
-
-
Chien, K.L.1
Hsu, H.C.2
Su, T.C.3
Chen, M.F.4
Lee, Y.T.5
Hu, F.B.6
-
34
-
-
84865125773
-
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism
-
Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722-9.
-
(2012)
J Am Coll Cardiol.
, vol.60
, Issue.8
, pp. 722-729
-
-
Helgadottir, A.1
Gretarsdottir, S.2
Thorleifsson, G.3
Holm, H.4
Patel, R.S.5
Gudnason, T.6
-
35
-
-
79960539641
-
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
European Association for Cardiovascular Prevention & Rehabilitation, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
-
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Association for Cardiovascular Prevention & Rehabilitation, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818.
-
(2011)
Eur Heart J.
, vol.32
, Issue.14
, pp. 1769-1818
-
-
Reiner, Z.1
Catapano, A.L.2
De Backer, G.3
Graham, I.4
Taskinen, M.R.5
Wiklund, O.6
-
36
-
-
0036790614
-
Statin therapy in acute coronary syndromes: Mechanistic insight into clinical benefit
-
Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22(10):1524-34.
-
(2002)
Arterioscler Thromb Vasc Biol.
, vol.22
, Issue.10
, pp. 1524-1534
-
-
Sposito, A.C.1
Chapman, M.J.2
-
38
-
-
77749248851
-
A systematic review and meta-analysis on the therapeutic equivalence of statins
-
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51.
-
(2010)
J Clin Pharm Ther.
, vol.35
, Issue.2
, pp. 139-151
-
-
Weng, T.C.1
Yang, Y.H.2
Lin, S.J.3
Tai, S.H.4
-
39
-
-
0037463820
-
Screening for statin-related toxicity: The yield of transaminase and creatine kinase measurements in a primary care setting
-
Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163(6):688-92.
-
(2003)
Arch Intern Med.
, vol.163
, Issue.6
, pp. 688-692
-
-
Smith, C.C.1
Bernstein, L.I.2
Davis, R.B.3
Rind, D.M.4
Shmerling, R.H.5
-
40
-
-
33645847841
-
An assessment of statin safety by muscle experts
-
National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel
-
Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C-76C.
-
(2006)
Am J Cardiol.
, vol.97
, Issue.8 A
-
-
Thompson, P.D.1
Clarkson, P.M.2
Rosenson, R.S.3
-
41
-
-
33845876333
-
Risks associated with statin therapy: A systematic overview of randomized clinical trials
-
Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788-97.
-
(2006)
Circulation.
, vol.114
, Issue.25
, pp. 2788-2797
-
-
Kashani, A.1
Phillips, C.O.2
Foody, J.M.3
Wang, Y.4
Mangalmurti, S.5
Ko, D.T.6
-
42
-
-
0021350001
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(13):351-64.
-
(1984)
JAMA.
, vol.251
, Issue.13
, pp. 351-364
-
-
-
43
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
SHARP Investigators
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
-
(2011)
Lancet
, vol.377
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
-
44
-
-
52649120889
-
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
-
SEAS Investigators
-
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-56.
-
(2008)
N Engl J Med.
, vol.359
, Issue.13
, pp. 1343-1356
-
-
Rossebo, A.B.1
Pedersen, T.R.2
Boman, K.3
Brudi, P.4
Chambers, J.B.5
Egstrup, K.6
-
45
-
-
78651473467
-
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
-
Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46(1):101-7.
-
(2011)
J Gastroenterol.
, vol.46
, Issue.1
, pp. 101-107
-
-
Park, H.1
Shima, T.2
Yamaguchi, K.3
Mitsuyoshi, H.4
Minami, M.5
Yasui, K.6
-
46
-
-
0016630250
-
Clofibrate and niacin in coronary heart disease
-
Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-81.
-
(1975)
JAMA.
, vol.231
, Issue.4
, pp. 360-381
-
-
-
47
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
HPS2-THRIVE Collaborative Group
-
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-91.
-
(2013)
Eur Heart J.
, vol.34
, Issue.17
, pp. 1279-1291
-
-
-
48
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
AIM-HIGH Investigators, Erratum in N Engl J Med. 2012;367(2):189
-
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-67. Erratum in N Engl J Med. 2012;367(2):189.
-
(2011)
N Engl J Med.
, vol.365
, Issue.24
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
Chaitman, B.R.4
Desvignes-Nickens, P.5
Koprowicz, K.6
-
49
-
-
0023232216
-
Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
-
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45.
-
(1987)
N Engl J Med.
, vol.317
, Issue.20
, pp. 1237-1245
-
-
Frick, M.H.1
Elo, O.2
Haapa, K.3
Heinonen, O.P.4
Heinsalmi, P.5
Helo, P.6
-
50
-
-
0035962077
-
Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
-
VA-HIT Study Group
-
Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585-91.
-
(2001)
JAMA.
, vol.285
, Issue.12
, pp. 1585-1591
-
-
Robins, S.J.1
Collins, D.2
Wittes, J.T.3
Papademetriou, V.4
Deedwania, P.C.5
Schaefer, E.J.6
-
51
-
-
0034604225
-
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
-
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21-7.
-
(2000)
Circulation.
, vol.102
, Issue.1
, pp. 21-27
-
-
-
52
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
FIELD study investigators, Erratum in Lancet. 2006;368(9545):1415, Lancet. 2006;368(9545):1420
-
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. Erratum in Lancet. 2006;368(9545):1415, Lancet. 2006;368(9545):1420
-
(2005)
Lancet.
, vol.366
, Issue.9500
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
Best, J.4
Scott, R.5
Taskinen, M.R.6
-
53
-
-
77952708442
-
Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
-
Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875-84.
-
(2010)
Lancet.
, vol.375
, Issue.9729
, pp. 1875-1884
-
-
Jun, M.1
Foote, C.2
Lv, J.3
Neal, B.4
Patel, A.5
Nicholls, S.J.6
-
54
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group, Erratum in: N Engl J Med. 2010;362(18):1748
-
Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. Erratum in: N Engl J Med. 2010;362(18):1748.
-
(2010)
N Engl J Med.
, vol.362
, Issue.17
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse III, J.R.4
Leiter, L.A.5
Linz, P.6
-
55
-
-
84868315176
-
Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: Systematic review and meta-analysis
-
Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ. 2012;345:e6698.
-
(2012)
BMJ.
, vol.345
-
-
Chowdhury, R.1
Stevens, S.2
Gorman, D.3
Pan, A.4
Warnakula, S.5
Chowdhury, S.6
-
56
-
-
84873667731
-
Omega 3 Fatty acids and cardiovascular outcomes: Systematic review and meta-analysis
-
Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(6):808-18.
-
(2012)
Circ Cardiovasc Qual Outcomes.
, vol.5
, Issue.6
, pp. 808-818
-
-
Kotwal, S.1
Jun, M.2
Sullivan, D.3
Perkovic, V.4
Neal, B.5
-
57
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
ILLUMINATE Investigators
-
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(12):2109-22.
-
(2007)
N Engl J Med.
, vol.357
, Issue.12
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
Grundy, S.M.4
Kastelein, J.J.5
Komajda, M.6
-
58
-
-
78650904300
-
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
-
Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52(1):78-86.
-
(2011)
J Lipid Res.
, vol.52
, Issue.1
, pp. 78-86
-
-
Ni, Y.G.1
Di Marco, S.2
Condra, J.H.3
Peterson, L.B.4
Wang, W.5
Wang, F.6
-
59
-
-
84884577104
-
In Process Citation
-
Santos RD, Gagliardi AC, Xavier HT, Casella Filho A, Araujo DB, Cesena FY, et al. [In Process Citation]. Arq Bras Cardiol. 2012;99(2 Suppl 2):1-28.
-
(2012)
Arq Bras Cardiol.
, vol.99
, Issue.2 SUPPL. 2
, pp. 1-28
-
-
Santos, R.D.1
Gagliardi, A.C.2
Xavier, H.T.3
Casella Filho, A.4
Araujo, D.B.5
Cesena, F.Y.6
-
60
-
-
0037188567
-
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
-
Ezetimibe Study Group
-
Gagné C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105(21):2469-75.
-
(2002)
Circulation.
, vol.105
, Issue.21
, pp. 2469-2475
-
-
Gagné, C.1
Gaudet, D.2
Bruckert, E.3
-
61
-
-
80051626920
-
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
-
Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging. 2011;6:27-35.
-
(2011)
Clin Interv Aging.
, vol.6
, pp. 27-35
-
-
Long, S.B.1
Blaha, M.J.2
Blumenthal, R.S.3
Michos, E.D.4
-
62
-
-
0037164314
-
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
-
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-30.
-
(2002)
Lancet.
, vol.360
, Issue.9346
, pp. 1623-1630
-
-
Shepherd, J.1
Blauw, G.J.2
Murphy, M.B.3
Bollen, E.L.4
Buckley, B.M.5
Cobbe, S.M.6
-
63
-
-
84879299109
-
Departamento de Aterosclerose. I Diretriz de prevenção da aterosclerose na infância e na adolescência da Sociedade Brasileira de Cardiologia
-
Sociedade Brasileira de Cardiologia
-
Sociedade Brasileira de Cardiologia. Departamento de Aterosclerose. I Diretriz de prevenção da aterosclerose na infância e na adolescência da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2005;85(supl 6):1-35.
-
(2005)
Arq Bras Cardiol.
, vol.85
, Issue.SUPPL. 6
, pp. 1-35
-
-
-
64
-
-
34247129908
-
Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing
-
American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing
-
McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948-67.
-
(2007)
Circulation.
, vol.115
, Issue.14
, pp. 1948-1967
-
-
McCrindle, B.W.1
Urbina, E.M.2
Dennison, B.A.3
Jacobson, M.S.4
Steinberger, J.5
Rocchini, A.P.6
-
65
-
-
36148976818
-
Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis
-
Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis. 2007;195(2):339-47.
-
(2007)
Atherosclerosis.
, vol.195
, Issue.2
, pp. 339-347
-
-
Arambepola, C.1
Farmer, A.J.2
Perera, R.3
Neil, H.A.4
-
66
-
-
77949349469
-
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
-
Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362(10):906-16.
-
(2010)
N Engl J Med.
, vol.362
, Issue.10
, pp. 906-916
-
-
Ladenson, P.W.1
Kristensen, J.D.2
Ridgway, E.C.3
Olsson, A.G.4
Carlsson, B.5
Klein, I.6
-
67
-
-
75749118959
-
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
-
Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325-31.
-
(2010)
Ann Rheum Dis.
, vol.69
, Issue.2
, pp. 325-331
-
-
Peters, M.J.1
Symmons, D.P.2
McCarey, D.3
Dijkmans, B.A.4
Nicola, P.5
Kvien, T.K.6
-
68
-
-
67549089990
-
Cardiovascular morbidity in psoriatic arthritis
-
Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131-5.
-
(2009)
Ann Rheum Dis.
, vol.68
, Issue.7
, pp. 1131-1135
-
-
Gladman, D.D.1
Ang, M.2
Su, L.3
Tom, B.D.4
Schentag, C.T.5
Farewell, V.T.6
-
69
-
-
0141676427
-
Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus
-
Thorburn CM, Ward MM. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(9):2519-23.
-
(2003)
Arthritis Rheum.
, vol.48
, Issue.9
, pp. 2519-2523
-
-
Thorburn, C.M.1
Ward, M.M.2
-
70
-
-
0029119711
-
Effect of pravastatin on outcomes after cardiac transplantation
-
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621-7.
-
(1995)
N Engl J Med.
, vol.333
, Issue.10
, pp. 621-627
-
-
Kobashigawa, J.A.1
Katznelson, S.2
Laks, H.3
Johnson, J.A.4
Yeatman, L.5
Wang, X.M.6
-
71
-
-
0030826180
-
Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
-
Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398-402.
-
(1997)
Circulation.
, vol.96
, Issue.5
, pp. 1398-1402
-
-
Wenke, K.1
Meiser, B.2
Thiery, J.3
Nagel, D.4
von Scheidt, W.5
Steinbeck, G.6
-
72
-
-
12344325443
-
Drug therapy in the heart transplant recipient: Part IV: Drug-drug interactions
-
Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation. 2005;111(2):230-9.
-
(2005)
Circulation.
, vol.111
, Issue.2
, pp. 230-239
-
-
Page III, R.L.1
Miller, G.G.2
Lindenfeld, J.3
-
73
-
-
70049114003
-
HMG CoA reductase inhibitors (statins) for dialysis patients
-
Jul
-
Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289.
-
(2009)
Cochrane Database Syst Rev.
, vol.8
, Issue.3
-
-
Navaneethan, S.D.1
Nigwekar, S.U.2
Perkovic, V.3
Johnson, D.W.4
Craig, J.C.5
Strippoli, G.F.6
-
74
-
-
65649116901
-
The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin
-
Shaw SM, Chaggar P, Ritchie J, Shah MK, Baynes AC, O'Neill N, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation. 2009;87(5):771-5.
-
(2009)
Transplantation.
, vol.87
, Issue.5
, pp. 771-775
-
-
Shaw, S.M.1
Chaggar, P.2
Ritchie, J.3
Shah, M.K.4
Baynes, A.C.5
O'Neill, N.6
-
76
-
-
34047237367
-
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
-
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77.
-
(2007)
JAMA.
, vol.297
, Issue.13
, pp. 1465-1477
-
-
Rossouw, J.E.1
Prentice, R.L.2
Manson, J.E.3
Wu, L.4
Barad, D.5
Barnabei, V.M.6
-
77
-
-
84865658424
-
Lipid-lowering therapy in persons with chronic kidney disease: A systematic review and meta-analysis
-
Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251-62.
-
(2012)
Ann Intern Med.
, vol.157
, Issue.4
, pp. 251-262
-
-
Upadhyay, A.1
Earley, A.2
Lamont, J.L.3
Haynes, S.4
Wanner, C.5
Balk, E.M.6
-
78
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
German Diabetes and Dialysis Study Investigators, Erratum in: N Engl J Med. 2005;353(15):1640
-
Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. Erratum in: N Engl J Med. 2005;353(15):1640.
-
(2005)
N Engl J Med.
, vol.353
, Issue.3
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
Marz, W.3
Olschewski, M.4
Mann, J.F.5
Ruf, G.6
-
79
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
AURORA Study Group
-
Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407.
-
(2009)
N Engl J Med.
, vol.360
, Issue.14
, pp. 1395-1407
-
-
Fellstrom, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
Holdaas, H.4
Bannister, K.5
Beutler, J.6
-
80
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
SHARP Investigators
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
-
(2011)
Lancet.
, vol.377
, Issue.9784
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
-
81
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
-
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504.
-
(2004)
N Engl J Med.
, vol.350
, Issue.15
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
Rader, D.J.4
Rouleau, J.L.5
Belder, R.6
-
82
-
-
0035804846
-
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
-
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-8.
-
(2001)
JAMA.
, vol.285
, Issue.13
, pp. 1711-1718
-
-
Schwartz, G.G.1
Olsson, A.G.2
Ezekowitz, M.D.3
Ganz, P.4
Oliver, M.F.5
Waters, D.6
-
83
-
-
33947517527
-
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial
-
Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272-8.
-
(2007)
J Am Coll Cardiol.
, vol.49
, Issue.12
, pp. 1272-1278
-
-
Patti, G.1
Pasceri, V.2
Colonna, G.3
Miglionico, M.4
Fischetti, D.5
Sardella, G.6
|